share_log

Canopy Growth | 10-Q: Q2 2025 Earnings Report

Canopy Growth | 10-Q: Q2 2025 Earnings Report

Canopy Growth | 10-Q：2025财年二季报
美股SEC公告 ·  2024/11/08 19:49

Moomoo AI 已提取核心信息

Canopy Growth Corporation reported Q2 fiscal 2025 net revenue of $63.0 million, down 9% year-over-year, while net loss from continuing operations improved to $131.6 million from $148.2 million. Gross margin percentage increased to 35% from 34% in the prior year period.The revenue decline was primarily driven by lower Canadian adult-use cannabis sales of $18.4 million, down 24% year-over-year, partially offset by growth in medical cannabis and international markets. Storz & Bickel revenue increased 32% to $15.9 million on strong growth in Germany and the U.S. The company continued its cost reduction initiatives, with selling, general and administrative expenses decreasing 28% to $41.7 million.During the quarter, the company made progress on its balance sheet initiatives, including selling shares through its ATM program for gross proceeds of $92.2 million and amending its Credit Facility to extend the maturity date to December 2026. The company ended the quarter with $228.4 million in cash and cash equivalents. Management remains focused on achieving sustainable profitability through cost optimization and strategic growth initiatives.
Canopy Growth Corporation reported Q2 fiscal 2025 net revenue of $63.0 million, down 9% year-over-year, while net loss from continuing operations improved to $131.6 million from $148.2 million. Gross margin percentage increased to 35% from 34% in the prior year period.The revenue decline was primarily driven by lower Canadian adult-use cannabis sales of $18.4 million, down 24% year-over-year, partially offset by growth in medical cannabis and international markets. Storz & Bickel revenue increased 32% to $15.9 million on strong growth in Germany and the U.S. The company continued its cost reduction initiatives, with selling, general and administrative expenses decreasing 28% to $41.7 million.During the quarter, the company made progress on its balance sheet initiatives, including selling shares through its ATM program for gross proceeds of $92.2 million and amending its Credit Facility to extend the maturity date to December 2026. The company ended the quarter with $228.4 million in cash and cash equivalents. Management remains focused on achieving sustainable profitability through cost optimization and strategic growth initiatives.
Canopy Growth Corporation报告了2025财年第二季度净营业收入为$6300万，同比下降9%，而持续经营的净亏损从$14820万改善至$13160万。毛利率从去年同期的34%上升至35%。营业收入的下降主要是由于加拿大成人大麻销售下降至$1840万，同比下降24%，部分被医疗大麻和国际市场的增长所抵消。Storz & Bickel的营业收入增长了32%，达$1590万，主要得益于在德国和美国的强劲增长。公司继续推进成本削减措施，销售、一般及行政费用下降28%，降至$4170万。在这一季度，公司在资产负债表上取得了进展，包括通过其ATm计划出售股份，获得总收入$9220万，并修订其信贷设施，将到期日延长至2026年12月。公司在季度末的现金及现金等价物为$22840万。管理层仍然专注于通过成本优化和战略增长举措实现可持续盈利。
Canopy Growth Corporation报告了2025财年第二季度净营业收入为$6300万，同比下降9%，而持续经营的净亏损从$14820万改善至$13160万。毛利率从去年同期的34%上升至35%。营业收入的下降主要是由于加拿大成人大麻销售下降至$1840万，同比下降24%，部分被医疗大麻和国际市场的增长所抵消。Storz & Bickel的营业收入增长了32%，达$1590万，主要得益于在德国和美国的强劲增长。公司继续推进成本削减措施，销售、一般及行政费用下降28%，降至$4170万。在这一季度，公司在资产负债表上取得了进展，包括通过其ATm计划出售股份，获得总收入$9220万，并修订其信贷设施，将到期日延长至2026年12月。公司在季度末的现金及现金等价物为$22840万。管理层仍然专注于通过成本优化和战略增长举措实现可持续盈利。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Petros Pharmaceuticals
    PTPI
    -- 0.2930
    坎伯兰药业
    CPIX
    -- 5.150
    OptiNose
    OPTN
    -- 6.000
    Talphera
    TLPH
    -- 0.670
    BioAge Labs
    BIOA
    -- 4.790
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！